L’IMPIEGO CLINICO DI UNA NUOVA CLASSE DI FARMACI ANTICOAGULANTI: GLI INIBITORI DIRETTI DELLA TROMBINA

Risultato della ricerca: Article

1 Citazione (Scopus)

Abstract

The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venous thrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thrombotic disease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulant drugs directly binding thrombin and blocking its interaction with fibrinogen. The group of direct thrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatran and its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantages compared to other anticoagulant drugs, and the particular pharmacokinetic properties of some of them could be very important for future management of thromboembolic prophylaxis. The efficacy and safety of these new drugs are evaluated in several clinical trials; however today only few clinical indications are available for the majority of them.
Lingua originaleItalian
pagine (da-a)739-746
Numero di pagine8
RivistaGiornale Italiano di Cardiologia
Volume7
Stato di pubblicazionePublished - 2006

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cita questo

@article{8497f36815d0461ba479bced8115de52,
title = "L’IMPIEGO CLINICO DI UNA NUOVA CLASSE DI FARMACI ANTICOAGULANTI: GLI INIBITORI DIRETTI DELLA TROMBINA",
abstract = "The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venous thrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thrombotic disease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulant drugs directly binding thrombin and blocking its interaction with fibrinogen. The group of direct thrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatran and its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantages compared to other anticoagulant drugs, and the particular pharmacokinetic properties of some of them could be very important for future management of thromboembolic prophylaxis. The efficacy and safety of these new drugs are evaluated in several clinical trials; however today only few clinical indications are available for the majority of them.",
author = "Salvatore Novo and Danilo Puccio",
year = "2006",
language = "Italian",
volume = "7",
pages = "739--746",
journal = "Giornale Italiano di Cardiologia",
issn = "0046-5968",
publisher = "Societa Italiana di Cardiologia",

}

TY - JOUR

T1 - L’IMPIEGO CLINICO DI UNA NUOVA CLASSE DI FARMACI ANTICOAGULANTI: GLI INIBITORI DIRETTI DELLA TROMBINA

AU - Novo, Salvatore

AU - Puccio, Danilo

PY - 2006

Y1 - 2006

N2 - The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venous thrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thrombotic disease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulant drugs directly binding thrombin and blocking its interaction with fibrinogen. The group of direct thrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatran and its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantages compared to other anticoagulant drugs, and the particular pharmacokinetic properties of some of them could be very important for future management of thromboembolic prophylaxis. The efficacy and safety of these new drugs are evaluated in several clinical trials; however today only few clinical indications are available for the majority of them.

AB - The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venous thrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thrombotic disease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulant drugs directly binding thrombin and blocking its interaction with fibrinogen. The group of direct thrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatran and its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantages compared to other anticoagulant drugs, and the particular pharmacokinetic properties of some of them could be very important for future management of thromboembolic prophylaxis. The efficacy and safety of these new drugs are evaluated in several clinical trials; however today only few clinical indications are available for the majority of them.

UR - http://hdl.handle.net/10447/17839

M3 - Article

VL - 7

SP - 739

EP - 746

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 0046-5968

ER -